LEDUC, AB - June 7, 2021- PBG BioPharma Inc., a life science company committed to becoming a world leader in the development and manufacturing of evidence-based biopharmaceuticals, nutraceuticals and medicinal cannabis products using its proprietary GenBioChem® Triple Fingerprinting Technology platform, announced today its plans to develop a phytochemical based, broad-spectrum anti-viral plant isolate to combat viral infections including the SARS-CoV-2 coronavirus (COVID-19).
As the COVID-19 pandemic shows little signs of slowing, growing concern is mounting over treatment options. Especially concerning are the appearance of variant strains and the uncertainty of their resistance to the vaccine. Now more than ever, the development of highly effective, broad-spectrum antiviral therapeutics in urgent need.
PBG is using its GenBioChem® platform to develop a proprietary, broad spectrum anti-viral plant isolate (PBG-007) directed at treating viral infections through modulating the cellular defense system. This project is supported in part by advisory services and research and development funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). A part of this project, in collaboration Dr. Harissios Vliagoftis, MD., from the Division of Pulmonary Medicine, Faculty of Medicine and Dentistry, University of Alberta aims to describe the immunomodulatory properties of these compounds that may support their potential to treat viral infections. This project will further the development of PBG-007 as a potential broad-spectrum anti-viral, aid in scaling-up manufacturing, and finally allow the company to advance the product to commercial production.
Of the project, Dr. Harissios Vliagoftis said, “Understanding the immune effects of these compounds may allow PBG to develop antiviral compounds that could be used clinically”.
“The launch of this project is reaffirming our continuous commitment to research and innovation in searching for much needed health products”, said PBG’s president and CEO, Dr. Jacqueline Shan.